Molecular Neurodegeneration's 2026 Journal Metrics Score is 17.1, ranking Q1 in Physiology and 1 other subfield. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 18.72.
Middle 50%: 106–202 days
99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025
Molecular Neurodegeneration accepts papers a median of 157 days after submission, including peer review and revisions. That is slower than 83% of comparable journals with PubMed timing data.
Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
245 of 369 works · same type, year & subfield
72 works · same type, year & subfield
Above field-year expectation
of 1,069 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 5.11, so its typical recent paper runs about 411% above its field benchmark.
66.4% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2016–2025
369 OpenAlex works · 2021–2024
OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.
Select a MeSH signal to see how much Molecular Neurodegeneration publishes on it, from PubMed counts for the last five complete years.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Physiology | Q1 |
| Neurology | Q1 |
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
Molecular Neurodegeneration's 2026 Journal Metrics Score is 17.1, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
Molecular Neurodegeneration's best quartile is Q1. By OpenAlex subfield: Q1 in Physiology; Q1 in Neurology. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Molecular Neurodegeneration will not match this score exactly. Compare journals using one source at a time.
Molecular Neurodegeneration accepts papers a median of 157 days after submission across 99 recent PubMed records with both dates; the middle half took 106–202 days. This includes peer review, editorial handling, and revisions.
PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Molecular Neurodegeneration, which includes peer review and revisions, has a median of 157 days. For the time to a first decision, check the journal's own website.
Molecular Neurodegeneration's median of 157 days from submission to acceptance is slower than 83% of comparable journals with PubMed timing data.
OpenAlex lists an indicative article processing charge of $2,990 USD for Molecular Neurodegeneration. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.
Comparable journals include Discover Neuroscience, Translational Neurodegeneration, Acta Neuropathologica, and Neurochemistry International. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.